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Abstract 
Diabetic complications include infection and cardiovascular disease. Within the 
immune system, host-pathogen and regulatory host-host interactions operate through 
binding of oligosaccharides by C-type lectin.  A number of C-type lectins recognise 
oligosaccharides rich in mannose and fucose – sugars with similar structures to 
glucose.  This raises the possibility that high glucose conditions in diabetes affect 
protein-oligosaccharide interactions via competitive inhibition.  Mannose binding 
lectin, soluble DC-SIGN & DC-SIGNR, and surfactant protein D, were tested for 
carbohydrate binding in the presence of glucose concentrations typical of diabetes, via 
surface plasmon resonance and affinity chromatography.  Complement activation 
assays were performed in high glucose.  DC-SIGN and DC-SIGNR expression in 
adipose tissues was examined via immunohistochemistry.  High glucose inhibited C-
type lectin binding to high-mannose glycoprotein and binding of DC-SIGN to 
fucosylated ligand (blood group B) was abrogated in high glucose.  Complement 
activation via the lectin pathway was inhibited in high glucose and also in high 
trehalose - a nonreducing sugar with glucoside stereochemistry.  DC-SIGN staining 
was seen on cells with DC morphology within omental and subcutaneous adipose 
tissues.  We conclude that high glucose disrupts C-type lectin function, potentially 
illuminating new perspectives on susceptibility to infectious and inflammatory disease 
in diabetes.  Mechanisms involve competitive inhibition of carbohydrate-binding 
within sets of defined proteins, in contrast to broadly indiscriminate, irreversible 
glycation of proteins. 
Introduction 
 
Defining characteristics of diabetes mellitus (DM) are the elevated concentrations of 
free glucose in the circulation and body fluids.  Lowering of glucose levels alleviates 
the pathological symptoms of the disease and improves the prognosis of the patients. 
In addition to perpetuating metabolic disturbances, high glucose directly causes tissue 
damage via irreversible glycation (1), a process that involves nonenzymatic, covalent 
attachment of glucose molecules to proteins via an amine-driven nucleophilic attack 
of the aldehyde group exposed in the glucose open-chain configuration.  Damaged 
proteins subsequently may exhibit impaired function.  However, glucose circulates 
predominantly in its thermodynamically stable pyranoside configuration, and in this 
cyclic form, it possesses biochemical features common to other carbohydrate 
molecules in the body such as oligosaccharide constituents and commensal bacterial 
cell wall substructures.  Important components of the innate immune system have 
evolved to recognize microbial polysaccharides and oligosaccharides rich in mannose 
and fucose.  Carbohydrate-binding proteins of the C-type lectin family play major 
roles in the execution of immunological responses towards these glycans and their 
associated pathogens (2).  For example, mannose-binding lectin (MBL), binds directly 
to mannoside/fucoside units on microbial surfaces and drives activation of the 
complement system, leading to opsonization, neutralization and stimulation of 
immune responses (3).  The complement system can drive both proinflammatory 
responses such as cell lysis, leucocyte recruitment and vascular permeability, but also 
anti-inflammatory processes such as apoptotic cell clearance (4-6).  Also, recent 
studies indicate that opsonic MBL influences antigen processing (7).  DC-SIGN 
(CD209) and DC-SIGNR (CD299) are type II transmembrane proteins believed to 
possess immunological functions such as cell adhesion and pathogen capture (8-12).  
Structural analyses of mannose binding by MBL, DC-SIGN and DC-SIGNR reveal 
the critical importance of the equatorial stereochemistry of the hydroxyl groups at the 
C3 and C4 positions of the pyranoside ring (13, 14).  Glucose shares identical 
stereochemistry at the C3 and C4 hydroxyls with mannose, varying only at the C2 
position, wherein the glucoside hydroxyl group assumes an equatorial orientation in 
contrast to an axial one (Figure 1).  Radioligand competition assays of 
monosaccharide binding to MBL, DC-SIGN and DC-SIGNR have shown similarities 
between glucose and mannose binding, with typical KI values in the region of 1-3 mM 
(15, 16).  Mannose does not exist in mammals as a free monosaccharide, although it is 
a constituent of host oligosaccharides.  However, glucose circulates typically at 
concentrations close to 5 mM and this can rise to 25 mM or more in DM, especially in 
postprandial conditions (17-19).  Therefore, we hypothesize that in DM, particularly 
poorly controlled DM, raised levels of glucose inhibit C-type lectin-mediated immune 
functions via reversible competitive inhibition, involving noncovalent interactions.  
Immunological disturbances such as depression of antimicrobial defences, poor 
wound healing, and dysregulated inflammatory responses represent major clinical 
complications in DM.  Furthermore, a number of C-type lectins, for example MBL, 
DC-SIGN and DC-SIGNR, exist in compartments of the circulation and vasculature 
such as plasma, monocytes, platelets and endothelial cells, such that noncovalent 
functional inhibition of these molecules could contribute to diabetic cardiovascular 
and renal complications. 
 
Materials and Methods 
 
Ethics statement 
Human tissues used in this study were obtained with informed written consent from 
healthy volunteers and approved by the University Hospitals Coventry and 
Warwickshire Ethics Committee in accordance with principles expressed in the 
Declaration of Helsinki. Data from human tissue samples were analyzed 
anonymously. 
 
Proteins and protein purification 
Recombinant rat mannose-binding lectin, soluble recombinant human DC-SIGN and 
DC-SIGNR extracellular domains, and native human surfactant protein D (SP-D) 
were generated as described previously (16, 20, 21). Purified recombinant HIV gp120 
was a gift from Prof K Reid, MRC Immunochemistry Unit, Oxford, UK.  All sugars, 
invertase, and buffer components were purchased from Sigma Chemical Co. (Poole, 
UK). 
 
Protein-Oligosaccharide Interaction Analysis Via Surface Plasmon Resonance (SPR) 
Streptavidin- or Neutravidin-coated sensor chips were treated with biotinylated HIV 
gp120 or biotinylated yeast invertase, selected as rich high mannose ligands. 
Sensorgrams were recorded at 25˚C using a BIAcore 2000 instrument (flow rate 10 
µL/min), or a Biorad ProteOn XPR36 biosensor (flow rate 30 µL/min), with each 
lectin analyte prepared at 40 µg/ml in 25 mM HEPES, 150 mM NaCl, 5 mM CaCl2, 
0.001% Tween-20 supplemented with D-glucose or D-trehalose at concentrations of 5, 
10, 15 and 20 mM.  No pre-incubation step was carried out and sensorgram data were 
collected in real time.  HEPES-NaCl buffer containing 5 mM EDTA was used to 
regenerate the sensor chip surface.  Sensorgram data were processed using supporting 
software (BIAevaluation or ProteOn Manager). 
 
Protein-Oligosaccharide Interaction Analysis Via Affinity Chromatography 
Glycorex B, a source of immobilized Blood Group B antigen, was used as affinity 
medium.  Columns of 1 ml settled resin were equilibrated in 25 mM HEPES, 150 mM 
NaCl, 5 mM CaCl2 supplemented with appropriate concentrations of test sugar (5 mM 
glucose, 20 mM glucose; 5 mM trehalose, 20 mM trehalose).  Soluble recombinant 
DC-SIGN (250 µL of a 2 mg/ml solution) was prepared in sugar-supplemented buffer 
and applied to the corresponding Glycorex B column.  Wash fractions (3  1 ml) in 
corresponding buffer were collected, followed by elution fractions (5  0.5 ml) in 25 
mM HEPES, 150 mM NaCl, 5 mM EDTA.  Aliquots of each fraction (15 µL) were 
visualized via SDS-PAGE using 4-12% Bis-Tris gels in the NuPAGE system 
(Invitrogen, Paisley, UK).  Positive binding to Group B oligosaccharide was 
determined through the presence of protein bands in the elution fractions.  Optical 
density at 280 nm was measured for each fraction. 
 
Complement Activation Assays 
The Wieslab ELISA-style complement activity assays were used throughout 
(Eurodiagnostica) following established protocols involving detection of terminal 
pathway components (22).  Assays were carried out measuring classical, alternative 
and lectin pathway activity within normal human serum in the presence of glucose, 
mannose, galactose, and fucose at concentrations between 0-100 mM.  Additional 
lectin pathway data were collected using trehalose.  Samples were measured in 
triplicate. 
 Immunohistochemistry 
Formalin-fixed adipose tissue sections, prepared at 3 µm thickness, were stained for 
DC-SIGN and DC-SIGNR using monoclonal antibodies (R&D Systems) at 800 ng/ml 
and 2 µg/ml respectively, in conjunction with a diaminobenzidine-immunoperoxidase 
detection kit (Vector Labs), and counterstaining with Mayers haematoxylin.  Negative 
controls were prepared by the omission of primary antibody, and also the inclusion of 
soluble recombinant DC-SIGN and DC-SIGNR as competitive inhibitors in the 
primary antibody solution at 10 µg/ml. 
 
Results 
Binding studies showed that high mannose recognition by the C-type lectins MBL, 
SP-D, DC-SIGNR and DC-SIGN was inhibited by increased concentrations of 
glucose (Figure 2).  The effects of high glucose on all recorded ligand binding events, 
visualised in real-time via surface plasmon resonance, were instantaneous given that 
samples were applied to the chip without a prior incubation step and thus insufficient 
conditions were available for effective glycation to take place.  MBL and DC-SIGNR 
binding was particularly sensitive, with apparent loss of all binding signal in 20 mM 
glucose.  SP-D showed a marked reduction in binding in the presence of 20 mM 
glucose and although binding of DC-SIGN was observed at 20 mM, it was 33% less 
than that obtained in 5 mM glucose.  We expanded the analysis of DC-SIGN binding 
using immobilized invertase, a microbial high-mannose glycoprotein with 
oligosaccharides similar to potential endogenous ligands such as ICAM-3.  Here we 
observed dose-dependent inhibition of glycoprotein recognition in the presence of 
elevated glucose.  Interestingly, the binding signal at 0 mM glucose was substantially 
greater than that observed with 5 mM glucose, consistent with previous radioligand 
competition assays (16).  Significantly, DC-SIGN binding was affected in a similar 
fashion using equivalent concentrations of trehalose, a nonreducing sugar incapable of 
glycation but with glucoside stereochemistry at equivalent C3 and C4 pyranosyl 
hydroxyls (Figure 1). 
DC-SIGN has also been shown to bind endogenous fucosylated 
oligosaccharides such as blood group antigens (23).  We examined the effects of high 
glucose on DC-SIGN binding to blood group B via affinity chromatography.  As seen 
in Figure 3, binding of DC-SIGN to Glycorex B resin was greatly reduced in the 
presence of 20 mM glucose, as seen by the abundance of protein recovered in the 
early wash region of the elution profile.  In contrast, DC-SIGN bound well to the 
Glycorex B column in the presence of 5 mM glucose, with the majority of protein 
eluting in the later, EDTA-containing fractions (Figure 3A and 3B).  A similar pattern 
was observed using 5 mM and 20 mM trehalose (Figure 3C and 3D).  As expected, 
MBL, SP-D, DC-SIGNR, and BSA did not bind to the columns (data not shown). 
Complement activation assays showed that classical and alternative pathway 
activities were not affected by elevated levels of glucose or other hexoses tested 
(Figure 4A and 4B).  However, activation of the lectin pathway was substantially 
affected, with complement activity being markedly reduced in the presence of 
glucose, mannose and fucose (Figure 4C).  As expected, mannose (IC50 = 5.8 ± 0.4) 
and fucose (IC50 = 3.7 ± 0.3) were more effective inhibitors relative to glucose (IC50 
= 14.4 ± 0.4), and galactose (IC50 = 20.8 ± 0.7) was less effective, reflecting previous 
MBL binding studies (15).  Analysis of lectin pathway activation in the presence of 
trehalose (IC50 = 23.8 ± 1.9) showed inhibition at higher concentrations, in a pattern 
similar to that observed for glucose (Figure 4D).  Interactions between C1q and 
carbohydrates has been reported (24), and thus it is surprising that monosaccharides 
did not appear to affect classical pathway activity.  However, the classical pathway 
assay protocol uses microwell plates coated with IgM heavy chain and we hypothesise 
that as a result, C1q interacts with this target via a mode of binding that operates 
independently of its putative carbohydrate binding sites. 
DC-SIGN and DC-SIGNR are plasma membrane proteins expressed on cells 
in a range of tissues including liver, lymph node and spleen.  We examined the 
expression of these glucose-sensitive receptors in adipose tissues, anatomically strong 
candidate sites for fostering intimate communications between immunity and 
metabolism (25).  Immunostaining for DC-SIGN demonstrated scattered, strongly 
immunopositive cells with dendritic morphology, in both omental (Figure 5A and 5B) 
and subcutaneous (Figure 5C and 5D) adipose tissues.  While occasional dendritic 
cells appear to be between adipocytes away from blood vessels, the majority appear 
perivascular in their distribution.  No immunostaining of other cell types in adipose 
tissue with anti-DC-SIGN was observed.  Positive staining for DC-SIGNR in adipose 
tissues was not observed. 
 
Discussion 
Host recognition of carbohydrate structures is essential for maintaining the healthy 
function of the mammalian immune system.  Disruption of selected oligosaccharide-
binding functions leads to impairment of immune processes, exemplified in hereditary 
human MBL deficiencies (26).  In a group of mammalian C-type lectins that bind to 
mannoside structures, we have shown that elevated concentrations of free glucose 
disrupt protein-oligosaccharide interactions via noncovalent, competitive inhibition.  
We also observe inhibition of both lectin binding and function in the presence of 
trehalose, which through its alpha-1,1 glycosidic linkage cannot adopt the open chain 
conformation necessary for protein glycation.  These findings provide novel 
mechanistic explanations for many pathological complications associated with 
diabetes, especially cases wherein glucose levels are difficult to control.  Gram-
negative infections are very common in diabetes, especially Pseudomonas infections.  
Cell wall structures associated with gram-negative bacteria are often rich in mannose 
and similar sugars, as are fungal cell walls such as those found in Candida organisms, 
similarly prevalent in diabetic infections.  C-type lectins such as MBL are known to 
participate in the neutralisation and control of these pathogens (27-29).  In addition, 
MBL is known to interact with apoptotic cells, enhancing their uptake and processing 
(30).  Impaired handling of apoptotic cells by complement proteins such as C1q has 
been shown to enhance or predispose to chronic inflammatory autoimmune diseases 
(31, 32), and whilst MBL deficiency may not contribute substantially to the breaking 
of immunological tolerance, the absence of adequate functional MBL may contribute 
to poorer resolution of inflammation.  Furthermore, epidemiological data describe an 
association between depressed MBL function, insulin resistance and obesity (33).  SP-
D is an important component of innate immunity in the lung and it has been suggested 
that glucose can inhibit SP-D binding in vivo wherein hyperglycaemic mice show 
greater susceptibility to viral infection (34).  Thus, our biochemical data support 
whole animal models with potential to be explored further. 
Activation of innate immune pathways with concomitant infiltration of 
adipose tissue macrophages leads to adipocyte inflammation, and this has been 
proposed as a fundamental process linking obesity to T2DM and atherosclerosis (35, 
36).  Studies have shown that expression levels of pro-inflammatory toll-like 
receptors on monocytes are elevated in patients with type 1 DM, this being supported 
by separate studies showing that insulin exerts significant suppressive effects on the 
expression of toll-like receptors on mononuclear leucocytes (37, 38).  DC-SIGN is 
expressed on dendritic cells and specialised macrophage populations that play vital 
roles in regulating inflammatory and adaptive immune responses (8).  DC-SIGN has 
been shown to participate in cross-talk with toll-like receptors, showing evidence of 
immunosuppressive effects (39).  Our novel observation of DC-SIGN-positive cells in 
both omental and subcutaneous compartments suggests that this receptor may 
participate in adipose tissue function.  Disruption of DC-SIGN-oligosaccharide 
interactions, typically associated with anti-inflammatory signalling and IL-10 
production (40), in hyperglycaemia could affect normal adipose DC/macrophage 
physiology and thus communications between metabolism and 
immunity/inflammation.  DC-SIGN is also expressed on platelets, suggesting that it 
may play a role in regulating coagulation and angiogenesis (41).  The glucose-
sensitive binding of DC-SIGN to blood group antigens, extensively expressed on 
erythrocytes, is particularly interesting within this context.  In addition, DC-SIGNR is 
expressed on specialised endothelia such as those found in lymph node and hepatic 
sinuses (11) proximal to large T cell repositories, and DC-SIGN has been reported to 
interact with vascular ICAM-2, suggesting that both of these receptors may be 
involved in lymphocyte and dendritic cell trafficking (10).  These functions may 
influence systemic inflammatory responses, including those located within adipose 
tissues. 
The reversible and fast-acting effects of glucose on C-type lectins contrasts 
directly with the slower kinetics of glycation and as such may contribute to a number 
of transient, postprandial effects of high glucose (42).  Our data using trehalose could 
reflect upon fundamental aspects of animal metabolic control, as trehalose rather than 
glucose serves as the major nutritional carbohydrate within insect haemolymph.  In an 
insect model of obesity, disease is associated with elevated trehalose, increased 
lethargy and a specific parasitic infection, all implicitly in the absence of glycation 
(43).  Insect C-type lectins with sugar-binding characteristics similar to those of 
mammals have been characterised and these proteins could potentially participate 
within processes regulating immunity, behaviour and metabolism (44).  Other 
mammalian mannose-selective lectins exist, including the mannose receptor (CD206) 
and pulmonary surfactant protein A.  Further elucidation of C-type lectin function, 
susceptibility to glucose, and participation within metabolic circuits heralds exciting 
opportunities for discovery within metabolic disease. 
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Figure Legends 
 
Figure 1. Sugar structures and stereochemistry 
Chemical structures of D-glucose, D-mannose and trehalose, indicating the relative 
orientation of hydroxyl groups at critical positions within the pyranoside ring. 
 
Figure 2. C-type lectin-glycoprotein interactions. 
Measurement of binding via surface plasmon resonance using immobilized HIV 
gp120 (A-D) and immobilized yeast invertase (E and F).  Glycoprotein binding by 
lectins SP-D (A), DC-SIGNR (B), MBL (C) and DC-SIGN (D-F) was recorded in the 
sugar concentrations indicated. 
 
Figure 3. DC-SIGN-Blood Group B interactions. 
Binding of soluble DC-SIGN to immobilized blood group antigen was carried out in 
the presence of 5 mM and 20 mM glucose (A and B) and 5 mM and 20 mM trehalose 
(C and D).  The relative appearance of elution profiles are illustrated by gel 
electrophoresis (A and C) and A280 measurements (B and D) of sequential fractions, 
with EDTA added to each profile at fraction 5. 
 
Figure 4. Complement Activation Assays. 
Measurement of classical (A), alternative (B) and lectin (C and D) pathway activation 
of complement in the presence of monosaccharides: glucose (Glc), mannose (Man), 
fucose (Fuc), galactose (Gal), and trehalose (Tre). 
 
Figure 5. Immunohistochemistry.  
Staining for DC-SIGN using the immunoperoxidase technique demonstrates strongly 
immunopositive cells (brown, marked with arrows) with dendritic morphology, in 
keeping with dendritic cells, in both omental (A and B) and subcutaneous (C and D) 
adipose tissue.  The larger, cells with clear, colourless cytoplasm that make up the 
majority of the tissue in these images represent adipocytes.  While occasional 
dendritic cells appear to be between adipocytes away from blood vessels, the majority 
appear perivascular in their distribution.  There is no immunostaining of other cell 
types in adipose tissue with anti-DC-SIGN.  The scale bar in panel a represents 40 
microns and pertains to panels A and C, while the scale bar in panel a represents 20 
microns and pertains to panels B and D. 
 
